Quantum-enhanced optimization for patient stratification in clinical trials

• URL: http://arxiv.org/abs/2601.11413v1
• Date: Fri, 16 Jan 2026 16:33:46 GMT
• Title: Quantum-enhanced optimization for patient stratification in clinical trials
• Abstract summary: Report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation.<n>Report shows that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: Clinical trials are notorious for their high failure rates and steep costs, leading to wasted time and resources spend, prolonged development timelines, and delayed patient access to new therapies. A key contributor to these failures is biological uncertainty, which complicates trial design and weakens the ability to detect true treatment effects. In particular, inadequate patient stratification often results in covariate imbalances across treatment arms, masking treatment effects and reducing statistical power, even when therapies are effective for specific patient subpopulations. This work presents an optimization-based, quantum-enhanced approach to patient stratification that explicitly minimizes covariate imbalance across numerical and categorical variables, without altering protocol design or trial endpoints. Using real clinical trial data, we demonstrate that hybrid quantum-classical optimization methods achieve high-quality stratification while scaling efficiently to larger cohorts. In our benchmark study, the quantum-enhanced pipeline delivered over a 100x improvement in computational efficiency compared to classical approaches, enabling faster iteration and practical deployment at scale. This report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation, reducing treatment-effect dilution and increasing trial sensitivity. Together, these results show that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.

Related papers

• ClinicalReTrial: A Self-Evolving AI Agent for Clinical Trial Protocol Optimization [31.528542179197572]
  ClinicalReTrial is a self-evolving AI agent framework for clinical trial reasoning.<n>Our method integrates failure diagnosis, safety-aware modification, and candidate evaluation in a closed-loop, reward-driven optimization framework.<n> Empirically, ClinicalReTrial improves 83.3% of trial protocols with a mean success probability gain of 5.7%.
  arXiv  Detail & Related papers  (2026-01-01T10:11:58Z)
• Beyond the ATE: Interpretable Modelling of Treatment Effects over Dose and Time [46.2482873419289]
  We propose a framework for modelling treatment effect trajectories as smooth surfaces over dose and time.<n>Our approach decouples the estimation of trajectory shape from the specification of clinically relevant properties.<n>We show that our method yields accurate, interpretable, and editable models of treatment dynamics.
  arXiv  Detail & Related papers  (2025-07-09T20:33:33Z)
• Learning Causally Predictable Outcomes from Psychiatric Longitudinal Data [6.09170287691728]
  Causal inference in longitudinal biomedical data remains a central challenge.<n>Our algorithm learns non-negative, clinically interpretable weights for outcome aggregation.<n>Our algorithm consistently outperforms state-of-the-art methods in recovering causal effects.
  arXiv  Detail & Related papers  (2025-06-19T21:56:30Z)
• Enhancing Treatment Effect Estimation via Active Learning: A Counterfactual Covering Perspective [61.284843894545475]
  Complex algorithms for treatment effect estimation are ineffective when handling insufficiently labeled training sets.<n>We propose FCCM, which transforms the optimization objective into the textitFactual and textitCounterfactual Coverage Maximization to ensure effective radius reduction during data acquisition.<n> benchmarking FCCM against other baselines demonstrates its superiority across both fully synthetic and semi-synthetic datasets.
  arXiv  Detail & Related papers  (2025-05-08T13:42:00Z)
• Statistical Learning for Heterogeneous Treatment Effects: Pretraining, Prognosis, and Prediction [40.96453902709292]
  We propose pretraining strategies that leverage a phenomenon in real-world applications.<n>In medicine, components of the same biological signaling pathways frequently influence both baseline risk and treatment response.<n>We use this structure to incorporate side information and develop models that can exploit synergies between risk prediction and causal effect estimation.
  arXiv  Detail & Related papers  (2025-05-01T05:12:14Z)
• Benchmarking Heterogeneous Treatment Effect Models through the Lens of Interpretability [82.29775890542967]
  Estimating personalized effects of treatments is a complex, yet pervasive problem. Recent developments in the machine learning literature on heterogeneous treatment effect estimation gave rise to many sophisticated, but opaque, tools. We use post-hoc feature importance methods to identify features that influence the model's predictions.
  arXiv  Detail & Related papers  (2022-06-16T17:59:05Z)
• SurvITE: Learning Heterogeneous Treatment Effects from Time-to-Event Data [83.50281440043241]
  We study the problem of inferring heterogeneous treatment effects from time-to-event data. We propose a novel deep learning method for treatment-specific hazard estimation based on balancing representations.
  arXiv  Detail & Related papers  (2021-10-26T20:13:17Z)
• Stochastic Intervention for Causal Inference via Reinforcement Learning [7.015556609676951]
  Central to causal inference is the treatment effect estimation of intervention strategies. Existing methods are mostly restricted to the deterministic treatment and compare outcomes under different treatments. We propose a new effective framework to estimate the treatment effect on intervention.
  arXiv  Detail & Related papers  (2021-05-28T00:11:22Z)
• Bayesian prognostic covariate adjustment [59.75318183140857]
  Historical data about disease outcomes can be integrated into the analysis of clinical trials in many ways. We build on existing literature that uses prognostic scores from a predictive model to increase the efficiency of treatment effect estimates.
  arXiv  Detail & Related papers  (2020-12-24T05:19:03Z)
• Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score [59.75318183140857]
  Estimating causal effects from randomized experiments is central to clinical research. Most methods for historical borrowing achieve reductions in variance by sacrificing strict type-I error rate control.
  arXiv  Detail & Related papers  (2020-12-17T21:10:10Z)
• Estimating heterogeneous survival treatment effect in observational data using machine learning [9.951103976634407]
  Methods for estimating heterogeneous treatment effect in observational data have largely focused on continuous or binary outcomes. Using flexible machine learning methods in the counterfactual framework is a promising approach to address challenges due to complex individual characteristics.
  arXiv  Detail & Related papers  (2020-08-17T01:02:14Z)
• Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints [84.09488581365484]
  Phase I dose-finding trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds becomes more complex. Most commonly used methods in practice focus on identifying a Maximum Tolerated Dose (MTD) by learning only from toxicity events. We present a novel adaptive clinical trial methodology that aims at maximizing the cumulative efficacies while satisfying the toxicity safety constraint with high probability.
  arXiv  Detail & Related papers  (2020-06-09T03:06:45Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.